Literature DB >> 15995044

Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia.

Frédéric Millot1, Philippe Traore, Joelle Guilhot, Brigitte Nelken, Thierry Leblanc, Guy Leverger, Dominique Plantaz, Yves Bertrand, Pierre Bordigoni, François Guilhot.   

Abstract

OBJECTIVE: The purpose of this study was to determine the clinical and biological characteristics at diagnosis in children and adolescents with chronic myelogenous leukemia (CML) in contemporary practice.
METHODS: Analysis was conducted on data from 3 prospective trials conducted in children and adolescents with CML. Forty pediatric patients were evaluated in 16 French pediatric oncology units between 1991 and 2003.
RESULTS: The disease predominately affected children who were older than 10 years (67% of the patients), with a higher prevalence in boys than girls (gender ratio: 1.5). Approximately 20% of cases were diagnosed incidentally. The main presenting symptoms were asthenia, weight loss, and complaints related to splenomegaly. Occasional patients presented with signs evocative of leukostasis. Symptoms were more common in patients with splenic enlargement, which was present in 70% of patients, and higher leukocyte counts. Markedly raised leukocyte counts were common (median white blood cell count: 242 x 10(9)/L). The age and the gender of the patients had no effect on the leukocyte count, the hemoglobin level, or the platelet count. A predominance of b3a2 transcript was observed in the 16 children who were studied for the type of chimeric BCR-ABL mRNA.
CONCLUSIONS: This is largest reported series of CML at diagnosis in children and adolescents. It shows that the characteristics of CML seem to differ in children compared with previously published adult series; in particular, the presenting leukocyte counts are often higher in children.

Entities:  

Mesh:

Year:  2005        PMID: 15995044     DOI: 10.1542/peds.2004-2473

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  21 in total

1.  Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.

Authors:  Nobuko Hijiya; Kirk R Schultz; Markus Metzler; Frederic Millot; Meinolf Suttorp
Journal:  Blood       Date:  2015-10-28       Impact factor: 22.113

2.  How I treat childhood CML.

Authors:  Jeffrey R Andolina; Steven M Neudorf; Seth J Corey
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

Review 3.  Management of chronic myeloid leukemia in childhood.

Authors:  Meinolf Suttorp; Louise Eckardt; Josephine Tabea Tauer; Frederic Millot
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

4.  Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.

Authors:  Yuli Cai; Chao Liu; Ye Guo; Xiaojuan Chen; Li Zhang; Yumei Chen; Yao Zou; Wenyu Yang; Xiaofan Zhu
Journal:  Int J Hematol       Date:  2021-01-01       Impact factor: 2.490

Review 5.  Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.

Authors:  Emma H McCafferty; Sohita Dhillon; Emma D Deeks
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

6.  Pediatric chronic myeloid leukemia with B-cell lymphoid blast crisis at presentation.

Authors:  Prasad Iyer; Peter Carey; Nick Bown; Sujith Samarasinghe
Journal:  Blood Res       Date:  2013-06-25

7.  Outcome prediction of chronic myeloid leukemia (CML) in children.

Authors:  Wing-Yan Leung; Daniel Ka-Leung Cheuk; Frankie Wai-Tsoi Cheng; Alex Wing-Kwan Leung; Ka-Ho Chiu; Karin Kar-Huen Ho; Chak-Ho Li; Godfrey Chi-Fung Chan
Journal:  Ann Hematol       Date:  2022-06-01       Impact factor: 4.030

8.  Comparative Study of Clinico-hematological Features, Molecular Spectrum and Response to Imatinib in Chronic Myelogenous Leukemia Patients: Pediatric and Adolescent Versus Adults.

Authors:  Anita Tahlan; Neelam Varma; Shano Naseem; Deepak Bansal; Jogeshwar Binota; Anil Sood; Man Updesh Singh Sachdeva; Pankaj Malhotra; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2017-05-09       Impact factor: 0.900

9.  The treatment of pediatric chronic myelogenous leukemia in the imatinib era.

Authors:  Jae Wook Lee; Nack Gyun Chung
Journal:  Korean J Pediatr       Date:  2011-03-31

10.  Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Jianqin Shan; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; William Wierda; Susan O'Brien; Jorge Cortes
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.